IGFBP2 and lung carcinoma: Previous studies have illustrated that IGFBP2 overexpression facilitates camptothecin resistance via regulating caspase-3 in an IGF-independent manner [14], and it also promotes EGFR-TKI erlotinib resistance by activating IGF-1R in lung cancer cells [15].